Key Takeaways
- Rocket Pharmaceuticals received FDA accelerated approval for KRESLADI, a groundbreaking gene therapy targeting severe leukocyte adhesion deficiency-I (LAD-I) in pediatric patients.
- Shares of RCKT surged up to 9% during premarket hours and maintained approximately 6% gains by Friday’s opening bell.
- This marks the first FDA-authorized gene therapy specifically designed to treat severe LAD-I, a deadly rare immune disorder affecting children.
- The company received a Rare Pediatric Disease Priority Review Voucher from the FDA, which Rocket intends to sell for additional capital.
- Friday’s approval follows a previous rejection in June 2024, after which Rocket provided supplementary clinical data.
Rocket Pharmaceuticals secured FDA approval for its gene therapy KRESLADI on Friday, propelling RCKT shares up to 9% during premarket hours before stabilizing at roughly 6% gains at market open.
Rocket Pharmaceuticals, Inc., RCKT
The FDA granted accelerated approval based on preliminary clinical evidence, particularly improvements in neutrophil CD18 and CD11a surface expression markers. Complete validation of clinical effectiveness will require long-term data collection from an active study and a post-approval monitoring registry.
KRESLADI, scientifically designated as marnetegragene autotemce, represents an autologous hematopoietic stem cell-based gene therapy. The treatment is authorized for children diagnosed with severe LAD-I resulting from biallelic ITGB2 gene mutations who lack access to an HLA-matched sibling donor for stem cell transplantation.
LAD-I constitutes an extremely rare genetic immune deficiency disorder. Patients experience persistent infections and face substantial early mortality risk without intervention. U.S. prevalence estimates range from one in 100,000 to one in 200,000 births, with approximately two-thirds presenting as severe cases.
KRESLADI represents the inaugural FDA-authorized gene therapy addressing this medical condition.
The regulatory path proved challenging. Last June, the FDA declined the biologics license application, requesting additional supporting data before proceeding with review completion.
Rocket resubmitted its BLA, receiving FDA acceptance in October 2024 with a target decision date of March 28, 2026—a timeline the regulatory agency honored precisely.
Priority Review Voucher Provides Additional Financial Value
Beyond the approval itself, the FDA awarded Rocket a Rare Pediatric Disease Priority Review Voucher. These transferable vouchers typically sell to pharmaceutical competitors for hundreds of millions of dollars, representing substantial financial value beyond product authorization.
Rocket indicated it will explore monetization strategies for the voucher to strengthen its financial position.
“The approval of KRESLADI represents an important milestone for the severe LAD-I community,” said CEO Gaurav Shah.
Development History and Scientific Foundation
The California Institute for Regenerative Medicine partially funded research underpinning KRESLADI’s development. The therapeutic intervention targets the ITGB2 gene, which produces a critical protein enabling white blood cells to combat infections effectively.
The Cranbury, New Jersey-headquartered biotechnology company has pursued this regulatory approval for multiple years.
The FDA established March 28, 2026 as the action deadline for the resubmitted BLA, and regulators delivered approval precisely on target.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
